Opinion: In generic drug plants in China and India, data falsification is still a problem
RAFIQ MAQBOOL/AP
The FDA touted approving more than 1,000 generic drugs in fiscal 2019. That's not good news if Indian and Chinese plants are manipulating FDA-required data.
No hay comentarios:
Publicar un comentario